Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zoledronic acid enhances the antitumor efficacy of the PSMA CAR-T cells for bone tumors, but impedes the ability to control metastases of prostate cancer in mice.

Cancer gene therapy·2026
Same author

Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant.

Nature biomedical engineering·2025
Same author

CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses.

Molecular cancer therapeutics·2025
Same author

A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants.

Signal transduction and targeted therapy·2025
Same author

Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages.

Signal transduction and targeted therapy·2025
Same author

Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.

Nature communications·2024

Related Experiment Video

Updated: Jul 12, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.7K

Chimeric Antigen Receptor-T Cell Therapy Decreases Distant Metastasis and Inhibits Local Recurrence Post-surgery in

Dan Li1, Lin Jiang1, Weilin Zhou1

  • 1Department of Biotherapy, The State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Human Gene Therapy
|November 2, 2023
PubMed
Summary

Chimeric antigen receptor (CAR)-T cell therapy effectively clears circulating tumor cells (CTCs) after surgery, reducing metastasis and preventing tumor relapse. This adjuvant therapy shows promise for improving cancer treatment outcomes.

Keywords:
CAR-TCTCsEpCAMlocal recurrencemetastasis

More Related Videos

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
05:05

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

10.7K
A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.0K

Related Experiment Videos

Last Updated: Jul 12, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.7K
Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
05:05

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

10.7K
A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Surgical Oncology

Background:

  • Distant metastasis and local tumor relapse are significant challenges in cancer surgery.
  • Circulating tumor cells (CTCs) and incomplete resection contribute to metastasis and recurrence.
  • Chimeric antigen receptor (CAR)-T cell therapy offers potential for targeting residual disease but lacks experimental validation in this context.

Purpose of the Study:

  • To investigate the efficacy of CAR-T cell therapy in preventing post-surgical metastasis and local recurrence.
  • To evaluate CAR-T cell therapy in a surgery-induced tumor metastasis model in mice.

Main Methods:

  • Development of a surgery-induced tumor metastasis model in immunocompetent mice.
  • Administration of EpCAM-specific CAR-T cells or Mock-T cells after tumor resection.
  • Monitoring of CTCs, pulmonary metastasis, local tumor relapse, and overall survival.

Main Results:

  • Subcutaneous tumor resection led to a significant increase in circulating tumor cells (CTCs).
  • EpCAM-specific CAR-T cell treatment effectively cleared CTCs post-surgery.
  • CAR-T cell therapy significantly reduced pulmonary metastasis and prolonged survival compared to mock treatment.
  • Local tumor relapse at the surgical site was markedly inhibited by EpCAM-CAR-T cell treatment.

Conclusions:

  • CAR-T cell therapy is effective in clearing CTCs following surgical tumor removal.
  • Adjuvant CAR-T cell therapy following surgery can inhibit tumor metastasis and reduce local recurrence.
  • This study supports CAR-T cell therapy as a potential adjuvant treatment to improve outcomes in cancer patients undergoing surgery.